-enzalutamide (xtandi) now approved in europe for the treatment of men with metastatic castration-resistant prostate cancer who are chemotherapy-naive

-enzalutamide (xtandi) now accepted in europe for the treatment of men with metastatic castration-resistant prostate … Today – 09:43 GMT ENP Newswire – 02 December 2014 Release date- 02122014 – Tokyo, -Astellas Pharma Inc. (TSE: 4503, ‘Astellas’) today announced that the European Payment (EC) has actually given a variation to [...] Read More